BioPharma Dive

@BioPharmaDive

We provide in-depth insight into the most significant news and trends shaping biotech and pharma. Sign up here: http://dive.pub/_BD9

Washington, D.C.

Joined July 2013

311Following

13KFollowers

Pinned

BioPharma Dive@BioPharmaDive · 4 h

Roche stops shipping Sarepta gene therapy in some countries outside US biopharmadive.com/news/roche-ele… $RHHBY by @NedPagliarulo

BioPharmaDive's tweet card. The Swiss company, which markets Elevidys abroad, said it believes the benefit-risk balance to treatment remains positive in Duchenne patients who can still walk, however.

330

Pinned

BioPharma Dive@BioPharmaDive · Jul 18

FDA to ask Sarepta to stop shipping Duchenne gene therapy biopharmadive.com/news/sarepta-f… $SRPT by @NedPagliarulo

BioPharmaDive's tweet card. The company had previously halted shipments to certain older patients following the deaths of two teenagers treated with the therapy, Elevidys.

632

BioPharma Dive@BioPharmaDive · 5 h

Abivax stock soars on trial data for ulcerative colitis drug biopharmadive.com/news/abivax-ob… $ABVX by Kristin Jensen

BioPharmaDive's tweet card. The French biotech is developing a new drug approach in a disease market that’s projected to grow to $30 billion by 2030.

306

BioPharma Dive@BioPharmaDive · 7 h

Dispatch emerges with $216M and plans for a ‘universal’ solid tumor therapy biopharmadive.com/news/disptach-… by @BentheFidler

BioPharmaDive's tweet card. The startup is using elements of gene and cell therapy to create medicines that could be useful against an array of tough-to-treat solid tumors.

297

BioPharma Dive@BioPharmaDive · Jul 22

News Roundup: Replimune drug rejected by FDA; Omega raises $647M biotech fund biopharmadive.com/news/replimune…

BioPharmaDive's tweet card. Analysts questioned whether the complete response letter Replimune received was evidence of changing approval standards at the FDA.

435

BioPharma Dive@BioPharmaDive · Jul 22

Sanofi to acquire vaccine biotech in billion-dollar deal biopharmadive.com/news/vicebio-v… $SNY by @Lilah_Alvarado

BioPharmaDive's tweet card. The French pharma will pay $1.15 billion upfront to buy Vicebio and gain access to non-mRNA vaccine candidates against RSV and metapneumovirus.

384

BioPharma Dive@BioPharmaDive · Jul 22

FDA panel elevates concerns over antidepressant use during pregnancy biopharmadive.com/news/fda-panel… by @Lilah_Alvarado

BioPharmaDive's tweet card. Experts on the panel shared many of the same views around SSRIs, arguing that the risks of the drugs during pregnancy are greater than currently accepted.

363

BioPharma Dive@BioPharmaDive · Jul 22

Sarepta stops Elevidys shipments after standoff with FDA biopharmadive.com/news/sarepta-p… $SRPT by @NedPagliarulo

BioPharmaDive's tweet card. Company CEO Doug Ingram said the pause was necessary for Sarepta to maintain a "productive and positive working relationship" with the regulator.

610

BioPharma Dive@BioPharmaDive · Jul 22

AstraZeneca grows US presence with $50B in spending plans biopharmadive.com/news/astrazene… $AZN by @NedPagliarulo

BioPharmaDive's tweet card. The $50 billion target, which AstraZeneca plans to meet by 2030, includes new manufacturing projects in Virginia and elsewhere, as well as R&D investment.

340

BioPharma Dive@BioPharmaDive · Jul 21

Former biotech executive appointed to lead FDA drug review office biopharmadive.com/news/fda-tidma… by @NedPagliarulo

BioPharmaDive's tweet card. George Tidmarsh, a Stanford University physician who founded Horizon Pharma and later ran La Jolla Pharma, was named head of the Center for Drug Evaluation and Research.

474

BioPharma Dive@BioPharmaDive · Jul 21

Alkermes narcolepsy drug headed for late-stage testing biopharmadive.com/news/alkermes-… $ALKS by @realJacobBell

BioPharmaDive's tweet card. Part of a class of therapies that boost “orexin” proteins, the drug just scored positive results in a Phase 2 trial. Analysts have guessed it could ultimately generate billions in sales.

393

BioPharma Dive@BioPharmaDive · Jul 21

5 questions on Sarepta, the FDA and a Duchenne gene therapy crisis biopharmadive.com/news/sarepta-f… $SRPT by @NedPagliarulo @BentheFidler

BioPharmaDive's tweet card. A standoff over Elevidys could have major consequences for Duchenne patients, gene therapy companies and the perception of the FDA.

674

BioPharma Dive@BioPharmaDive · Jul 18

News Roundup: Bristol Myers’ Reblozyl falls short in Phase 3; Blenrep voted down by FDA panel biopharmadive.com/news/bristol-m…

BioPharmaDive's tweet card. The anemia treatment missed its main goal in a myelofibrosis study. Meanwhile, Blenrep's return to the U.S. market may have become more difficult after the negative advisory committee vote.

443

BioPharma Dive@BioPharmaDive · Jul 18

Panel urges FDA to remove warnings on hormonal menopause therapy biopharmadive.com/news/fda-hormo… by @Lilah_Alvarado

BioPharmaDive's tweet card. A meeting held by the FDA Thursday spotlighted debate over black box warnings that have limited use of hormone treatment for hot flashes.

343

BioPharma Dive@BioPharmaDive · Jul 18

Sarepta reports patient death in limb-girdle trial, compounding concerns on gene therapy risks biopharmadive.com/news/sarepta-l… $SRPT by @BentheFidler

BioPharmaDive's tweet card. According to multiple reports, a 51-year-old man with limb-girdle muscular dystrophy died from acute liver failure after receiving an experimental treatment in a Phase 1 study.

589

BioPharma Dive@BioPharmaDive · Jul 18

#Biotech startup funding dried up in second quarter, HSBC finds biopharmadive.com/news/biotech-v… by @gwendolynawu

BioPharmaDive's tweet card. Overall venture funding, as well as “first financing” rounds, fell significantly in the second quarter, erasing what had been a fast start to 2025, according to HSBC.

839

BioPharma Dive@BioPharmaDive · Jul 17

Novartis CEO says resolution on Trump plan to cut US drug prices will take time biopharmadive.com/news/novartis-… $NVS by @NedPagliarulo

BioPharmaDive's tweet card. Conversations with the Trump administration on its “most favored nation” policy have been productive, the executive said Thursday. But the details, and their potential consequences, are still not...

333

BioPharma Dive@BioPharmaDive · Jul 17

Sarepta to lay off about 500 employees after Duchenne gene therapy setbacks biopharmadive.com/news/sarepta-l… $SRPT by @BentheFidler

BioPharmaDive's tweet card. On a conference call, CEO Doug Ingram said the decision to cut 36% of the company's staff and halt several drug programs was essential to ensuring Sarepta's "long-term viability."

662

BioPharma Dive@BioPharmaDive · Jul 17

Bristol Myers, Pfizer to offer Eliquis at a discount for some patients biopharmadive.com/news/pfizer-br… $BMY $PFE by @BentheFidler

BioPharmaDive's tweet card. The program is the latest example of pharmaceutical companies bypassing traditional drug distribution channels for people who aren’t insured or are willing to pay cash for their medications.

361

BioPharma Dive@BioPharmaDive · Jul 16

AstraZeneca rare disease drug fails key trial tests biopharmadive.com/news/astrazene… $AZN by @gwendolynawu

BioPharmaDive's tweet card. Anselamimab, which AstraZeneca acquired via Caelum Biosciences, missed its primary goal in two late-stage trials, but appeared to have some benefit in a subgroup of patients.

540